NRIX
Income statement / Annual
Last year (2025), Nurix Therapeutics, Inc.'s total revenue was $83.98 M,
an increase of 53.95% from the previous year.
In 2025, Nurix Therapeutics, Inc.'s net income was -$264.46 M.
See Nurix Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
11/30/2025 |
11/30/2024 |
11/30/2023 |
11/30/2022 |
11/30/2021 |
11/30/2020 |
11/30/2019 |
11/30/2018 |
| Operating Revenue |
$83.98 M |
$54.55 M |
$76.99 M |
$38.63 M |
$29.75 M |
$17.82 M |
$31.12 M |
$37.45 M |
| Cost of Revenue |
$18.86 M
|
$221.63 M
|
$189.15 M
|
$184.50 M
|
$116.43 M
|
$66.49 M
|
$45.03 M
|
$40.51 M
|
| Gross Profit |
$65.12 M
|
-$167.08 M
|
-$112.16 M
|
-$145.87 M
|
-$86.68 M
|
-$48.67 M
|
-$13.91 M
|
-$3.07 M
|
| Gross Profit Ratio |
0.78
|
-3.06
|
-1.46
|
-3.78
|
-2.91
|
-2.73
|
-0.45
|
-0.08
|
| Research and Development Expenses |
$308.16 M
|
$221.63 M
|
$189.15 M
|
$184.50 M
|
$116.43 M
|
$66.49 M
|
$45.03 M
|
$40.51 M
|
| General & Administrative Expenses |
$52.74 M
|
$45.94 M
|
$42.90 M
|
$38.00 M
|
$31.20 M
|
$16.31 M
|
$8.33 M
|
$6.67 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$52.74 M
|
$45.94 M
|
$42.90 M
|
$38.00 M
|
$31.20 M
|
$16.31 M
|
$8.33 M
|
$6.67 M
|
| Other Expenses |
-$10.12 M
|
-$221.63 M
|
-$189.15 M
|
-$184.50 M
|
-$116.43 M
|
-$66.49 M
|
-$45.03 M
|
-$40.51 M
|
| Operating Expenses |
$350.79 M
|
$45.94 M
|
$42.90 M
|
$38.00 M
|
$31.20 M
|
$16.31 M
|
$8.33 M
|
$6.67 M
|
| Cost And Expenses |
$369.65 M
|
$267.58 M
|
$232.05 M
|
$222.49 M
|
$147.64 M
|
$82.80 M
|
$53.35 M
|
$47.19 M
|
| Interest Income |
$21.97 M
|
$19.73 M
|
$11.12 M
|
$3.51 M
|
$823.00 K
|
$1.21 M
|
$776.00 K
|
$818.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$18.86 M
|
$8.02 M
|
$6.13 M
|
$4.15 M
|
$1.99 M
|
$2.18 M
|
$2.35 M
|
$2.99 M
|
| EBITDA |
-$244.84 M |
-$205.01 M |
-$148.93 M |
-$179.72 M |
-$115.90 M |
-$62.80 M |
-$19.88 M |
-$6.75 M |
| EBITDA Ratio |
-2.92
|
-3.76
|
-1.93
|
-4.65
|
-3.9
|
-3.52
|
-0.64
|
-0.18
|
| Operating Income Ratio |
-3.4
|
-3.91
|
-2.01
|
-4.76
|
-3.96
|
-3.65
|
-0.71
|
-0.26
|
| Total Other Income/Expenses Net |
$21.97 M
|
$19.73 M
|
$11.12 M
|
$3.51 M
|
$823.00 K
|
$1.21 M
|
$776.00 K
|
$818.00 K
|
| Income Before Tax |
-$263.70 M
|
-$193.30 M
|
-$143.95 M
|
-$180.36 M
|
-$117.06 M
|
-$63.78 M
|
-$21.46 M
|
-$8.92 M
|
| Income Before Tax Ratio |
-3.14
|
-3.54
|
-1.87
|
-4.67
|
-3.93
|
-3.58
|
-0.69
|
-0.24
|
| Income Tax Expense |
$760.00 K
|
$270.00 K
|
$0.00
|
$0.00
|
$131.00 K
|
-$20.54 M
|
$239.00 K
|
$507.00 K
|
| Net Income |
-$264.46 M
|
-$193.57 M
|
-$143.95 M
|
-$180.36 M
|
-$117.19 M
|
-$43.24 M
|
-$21.70 M
|
-$9.43 M
|
| Net Income Ratio |
-3.15
|
-3.55
|
-1.87
|
-4.67
|
-3.94
|
-2.43
|
-0.7
|
-0.25
|
| EPS |
-3.05 |
-2.88 |
-2.65 |
-3.71 |
-2.73 |
-2.76 |
-0.56 |
-0.59 |
| EPS Diluted |
-3.05 |
-2.88 |
-2.65 |
-3.71 |
-2.73 |
-2.76 |
-0.56 |
-0.59 |
| Weighted Average Shares Out |
$86.67 M
|
$67.12 M
|
$54.34 M
|
$48.61 M
|
$42.90 M
|
$15.67 M
|
$38.85 M
|
$16.11 M
|
| Weighted Average Shares Out Diluted |
$86.67 M
|
$67.12 M
|
$54.34 M
|
$48.61 M
|
$42.90 M
|
$15.67 M
|
$38.85 M
|
$16.11 M
|
| Link |
|
|
|
|
|
|
|
|
